-
公开(公告)号：US10533057B2
公开(公告)日：2020-01-14
申请号：US15569495
申请日：2016-05-13
Applicant: MORPHOSYS AG
Inventor： Stéphane LeClair , Jan Endell , Stefan Härtle
IPC: A61K39/395 , C07K16/28 , A61P35/00 , A61K9/00 , A61K31/573
Abstract: The present disclosure relates to the treatment of multiple myeloma. Monoclonal antibody MOR202 is efficacious when administered to patient at certain dosage regimens.
-
公开(公告)号：US20210130461A1
公开(公告)日：2021-05-06
申请号：US17084783
申请日：2020-10-30
Applicant: MORPHOSYS AG
Inventor： Jan Endell , Rainer Boxhammer , Dominik Pretscher
Abstract: The present disclosure is directed to a combination therapy comprising an anti-CD19 antibody or antibody fragment thereof and gamma delta T-cells (γδ T-cells) for use in the treatment of leukemia or lymphoma.
-
3.发明申请公开(公告)号：US20180153892A1
公开(公告)日：2018-06-07
申请号：US15572914
申请日：2016-05-25
Applicant: MORPHOSYS AG
Inventor： Jan Endell , Rainer Boxhammer , Mark Winderlich
IPC: A61K31/519 , A61K39/395 , A61K47/68 , C07K16/28 , A61P35/00
CPC classification number: A61K31/519 , A61K39/39558 , A61K47/68 , A61K2039/505 , A61P35/00 , C07K16/2803 , C07K16/2896 , C07K2317/24 , C07K2317/732 , A61K2300/00
Abstract: The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a Bruton's tyrosine kinase (BTK) inhibitor for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.
-
公开(公告)号：US11591406B2
公开(公告)日：2023-02-28
申请号：US16693904
申请日：2019-11-25
Applicant: MORPHOSYS AG
Inventor： Stéphane LeClair , Jan Endell , Stefan Härtle
IPC: A61K39/00 , C07K16/28 , A61P35/00 , A61K9/00 , A61K31/573
Abstract: The present disclosure relates to the treatment of multiple myeloma. Monoclonal antibody MOR202 is efficacious when administered to patient at certain dosage regimens.
-
公开(公告)号：US10308722B2
公开(公告)日：2019-06-04
申请号：US15670811
申请日：2017-08-07
Applicant: MORPHOSYS AG
Inventor： Lisa Rojkjaer , Rainer Boxhammer , Jan Endell , Mark Winderlich , Christofer Samuelsson
IPC: A61K39/395 , C07K16/40 , A61K31/454 , A61K38/05 , A61K45/06 , C07K16/28 , C07K16/30 , A61K31/69 , A61K38/07 , A61K39/00
Abstract: The present disclosure is directed to a method of treating multiple myeloma or non-hodgkins lymphoma with a pharmaceutical composition comprising an anti-CD38 antibody in combination with thalidomide, lenalidomide, or pomalidomide.
-
Patent Agency Ranking
公开(公告)号：US09579378B2
公开(公告)日：2017-02-28
申请号：US14430801
申请日：2013-09-24
Applicant: MORPHOSYS AG
Inventor： Jan Endell , Lisa Rojkjaer
IPC: A61K38/00 , A61K39/395 , C07K16/28 , A61K31/198 , A61K39/00
CPC classification number: A61K39/39558 , A61K31/198 , A61K39/3955 , A61K2039/545 , C07K16/2896 , A61K2300/00
Abstract: The present disclosure describes a pharmaceutical combination of an anti-CD38 antibody and melphalan.
Abstract translation: 本公开描述了抗CD38抗体和美法仑的药物组合。
-
公开(公告)号：US20150238603A1
公开(公告)日：2015-08-27
申请号：US14430801
申请日：2013-09-24
Applicant: MORPHOSYS AG
Inventor： Jan Endell , Lisa Rojkjaer
IPC: A61K39/395 , A61K31/198
CPC classification number: A61K39/39558 , A61K31/198 , A61K39/3955 , A61K2039/545 , C07K16/2896 , A61K2300/00
Abstract: The present disclosure describes a pharmaceutical combination of an anti-CD38 antibody and melphalan.
Abstract translation: 本公开描述了抗CD38抗体和美法仑的药物组合。
-
公开(公告)号：US20150017160A1
公开(公告)日：2015-01-15
申请号：US14500366
申请日：2014-09-29
Applicant: MORPHOSYS AG
Inventor： Lisa Rojkjaer , Rainer Boxhammer , Jan Endell , Mark Winderlich , Christofer Samuelsson
IPC: A61K39/395 , A61K31/454
CPC classification number: C07K16/40 , A61K31/454 , A61K31/69 , A61K38/05 , A61K38/07 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K2039/505 , C07K16/28 , C07K16/2896 , C07K16/3061 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/76 , A61K2300/00
Abstract: The present disclosure describes a pharmaceutical combination of an anti-CD38 antibody and lenalidomide and a pharmaceutical combination of an anti-CD38 antibody and bortezomib.
Abstract translation: 本公开描述了抗CD38抗体和来那度胺的药物组合以及抗CD38抗体和硼替佐米的药物组合。
-
公开(公告)号：US20200079871A1
公开(公告)日：2020-03-12
申请号：US16693904
申请日：2019-11-25
Applicant: MORPHOSYS AG
Inventor： Stéphane LeClair , Jan Endell , Stefan Härtle
IPC: C07K16/28 , A61P35/00 , A61K9/00 , A61K31/573
Abstract: The present disclosure relates to the treatment of multiple myeloma. Monoclonal antibody MOR202 is efficacious when administered to patient at certain dosage regimens.
-
公开(公告)号：US20190241656A1
公开(公告)日：2019-08-08
申请号：US16342645
申请日：2017-10-27
Applicant: MORPHOSYS AG
Inventor： Jan Endell , Konstantin Petropoulos , Peter Kelemen , Ranier Boxhammer , Markus Rückert
IPC: C07K16/28 , A61K31/496 , A61P35/02 , A61K9/00
CPC classification number: C07K16/2803 , A61K9/0019 , A61K31/496 , A61K39/395 , A61P35/02 , A61K2300/00
Abstract: The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a BCL-2 inhibitor for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.
-
-
-
-
-
-
-
-
-
Search Results
17
records
(took 0.016 seconds)
